Anadolu Medical Center (Turkish: Anadolu Sağlık Merkezi) is a hospital in Gebze, Kocaeli, Turkey. It is located in Çayırova on the highway D.100 at the Bayramoğlu exit, close to Sabiha Gökçen International Airport. Established by Anadolu Foundation, the hospital was built on 186,000 m2 (2,000,000 sq ft) of land and was opened on February 12, 2005. It consists of 209 beds, 59 intensive care beds and 8 operating rooms. The parking lot is capable of 350 cars. The medical center was initially as a specialized cancer center but then it transformed into a multidisciplinary hospital. Anadolu is one of the most popular centers of bone transplantation BMT in the Mediterranean with up to 22 stem cell transplants can be performed simultaneously.It has ISO 9001–2000 (Quality Management System), ISO 14001 (Environment Management System), OHSAS 18001 (Work Health and Safety) and JCI (Joint Commission International) certifications. The hospital is affiliated with the Johns Hopkins Hospital in the United States through Johns Hopkins Medicine International.IMRT and Cyberknife are two of the latest technologies used in cancer treatment developed at the Anadolu Medical Center. The hospital also provides multidisciplinary care, free check ups, patient education, first aid courses, and courses related to preventive medicine. Its cancer centre is an OECI-designated clinical cancer centre.Anadolu Medical Center has outpatient clinics in Istanbul at Ataşehir ..
To map and critically appraise the current literature on Artificial Intelligence (AI) applications in emergency general surgery, with a focus on clinical decision-support tools for preoperative risk stratification and intraoperative assistance, and to identify ethical, structural, and regulatory barriers to implementation. A scoping review was conducted within the ARIES project, following established methodological frameworks. Relevant studies evaluating AI-based tools in emergency surgical settings were systematically identified and analyzed. The literature describes AI applications mainly in two domains: preoperative decision support, including risk prediction and diagnostic or triage models for acute abdominal and traumatic conditions, and intraoperative assistance, largely focused on computer vision–based systems for anatomical recognition, safety guidance, and navigation in minimally invasive emergency procedures. Additional contributions address training and telementoring platforms, as well as cross-cutting ethical, legal, and regulatory considerations relevant to AI adoption in emergency surgical care. AI has the potential to complement emergency surgeons’ clinical judgment, but its routine adoption in emergency surgical practice remains limited. Addressing methodological, ethical, and regulatory challenges, together with the development of robust data infrastructures and targeted training pathways, is essential to support safe, effective, and equitable implementation in acute care settings. In addition, the lack of dedicated investment and sustainable funding models for large-scale clinical implementation and prospective evaluation represents a critical barrier to the translation of AI from research into routine emergency surgical practice.
Study Design:Single-center retrospective cohort study. Purpose:To evaluate tumor control, neurological recovery, perioperative morbidity, and long-term biomechanical stability of unilateral hemilaminectomy (UH) for adult intradural spinal tumors. Overview of Literature:Total laminectomy disrupts stabilizing posterior elements and may necessitate instrumentation for deformity. UH preserves the contralateral posterior complex, offering comparable resection rates, reduced perioperative morbidity, and shorter hospitalization. However, most studies on UH involve small, methodologically heterogeneous samples, with limited long-term data on neurological recovery and mechanical stability without fusion. Methods:Adult patients (≥18 years) undergoing UH for intradural spinal tumors (2015-2025) were retrospectively identified from a prospectively maintained database. Pediatric patients and those with extradural tumors were excluded. Primary endpoints were the extent of resection (gross total resection [GTR] vs. subtotal resection [STR]) and biomechanical stability (segmental instability or delayed fusion). Secondary outcomes included operative time, blood loss, length of stay, transfusion, postoperative complications, and unplanned reoperation. Neurological function (American Spinal Injury Association Impairment Scale [AIS] C/D vs. AIS E) was analyzed using Fisher's exact and McNemar tests. A focused literature review summarized comparative evidence on UH versus total laminectomy. Results:Of the 405 UH procedures screened, 136 adult intradural tumors met the criteria (108 extramedullary; 28 intramedullary). The average operative time, blood loss, and hospital stay were 91.0±13.5 minutes, 58.5±16.6 mL, and 3.97±1.05 days, respectively. One patient developed postoperative complications (cerebrospinal fluid leak requiring duraplasty); no transfusions or instrumented fusion were required. GTR was achieved in 95.6% cases; six intramedullary astrocytomas underwent STR followed by stereotactic radiotherapy. Neurological status improved significantly in extramedullary tumors (p<0.001), and no radiographic recurrence or delayed fusion occurred during follow-up. Conclusions:UH allows high resection rates, neurological improvement, low morbidity, and durable mechanical stability in intradural tumors, supporting its use as a tissue-preserving alternative to wider posterior exposure.
Acquired aplastic anemia (AA) is a rare blood disorder causing hypocellular bone marrow due to immune damage to hematopoietic stem cells, leading to low blood cell counts. This study investigates the demographics, treatment patterns, and clinical outcomes of AA in Turkiye. In this non-interventional, retrospective descriptive study, data of 274 patients (Female/Male: 4/5) diagnosed with AA between September 1, 2011, and September 1, 2021, were collected from 16 centers. Severe and very severe AA was diagnosed in 72
Background: Surgical site infections (SSIs) remain a major cause of morbidity, mortality, and inequity worldwide. Many SSIs are preventable and represent an important indicator of surgical quality and patient safety. Methods: Evidence and implementation experiences on SSI prevention were reviewed, focusing on infection prevention and control (IPC), antimicrobial stewardship (AMS), antimicrobial resistance (AMR), quality improvement, surveillance, safety culture, human factors, and emerging technologies. Results: Multimodal, context-adapted IPC interventions can substantially reduce SSI incidence without major capital investment. Persistent gaps in infrastructure, guideline implementation, surveillance, and environmental controls remain important challenges. AMR further emphasizes the need to integrate AMS into surgical safety frameworks. Artificial intelligence and objective diagnostic technologies may improve surveillance and early SSI detection. Summary: SSI prevention is both a clinical necessity and an ethical imperative. Global surgery strategies should integrate IPC, AMS, surveillance, safety culture, and innovative technologies to advance equity, quality, and safety in surgical care worldwide.
Background: Poly(ADP-ribose) polymerase (PARP) inhibitors have been established as a first-line maintenance therapy in advanced epithelial ovarian cancer (EOC) following platinum-based chemotherapy. While phase III trials have demonstrated significant progression-free survival (PFS) benefits with olaparib and niraparib, real-world data remain limited. Methods: This retrospective, multicenter real-world study included 179 patients with newly diagnosed epithelial ovarian treated with first-line maintenance olaparib or niraparib across 33 centers in Türkiye between January 2014 and March 2025. Clinical, pathological, and molecular data-including BRCA (Breast Cancer Susceptibility Gene) mutation status, origin, and variant classification-was collected. The primary endpoint was PFS, and secondary endpoints included overall survival (OS) and safety. Survival outcomes were analyzed using Kaplan-Meier methods. Results: Of 179 patients, 110 received olaparib and 69 received niraparib. BRCA mutations were present in 88.3% of patients, while 11.7% had unknown HRD status. Median follow-up was 16.5 months, and median PFS was not reached. Estimated PFS rates for the overall cohort were 91.0% at 6 months, 83.0% at 12 months, and 64.0% at 24 months. In the olaparib cohort, BRCA-mutant patients demonstrated PFS rates of 89%, 78%, 73%, and 64% at 6, 12, 18, and 24 months, respectively. In the niraparib cohort, corresponding PFS rates among BRCA-mutant patients were 87% at 6 months and 75% at 12 months. Patients harboring pathogenic BRCA variants experienced longer PFS compared with those with likely pathogenic variants. Any-grade adverse events occurred in 73.7% of patients, and grade 3-4 events in 29.6%, with hematologic toxicities predominating. Dose interruptions were more frequent with niraparib, while treatment discontinuation rates were low in both groups. No cases of myelodysplastic syndrome or acute myeloid leukemia were observed. Conclusions: In this large multicenter real-world cohort, first-line maintenance therapy with olaparib and niraparib provided durable PFS benefit in patients with advanced EOC, particularly among those with pathogenic BRCA mutations, confirming their effectiveness and manageable safety profiles in routine clinical practice.